JP2011046700A5 - - Google Patents

Download PDF

Info

Publication number
JP2011046700A5
JP2011046700A5 JP2010171260A JP2010171260A JP2011046700A5 JP 2011046700 A5 JP2011046700 A5 JP 2011046700A5 JP 2010171260 A JP2010171260 A JP 2010171260A JP 2010171260 A JP2010171260 A JP 2010171260A JP 2011046700 A5 JP2011046700 A5 JP 2011046700A5
Authority
JP
Japan
Prior art keywords
solvate
pharmaceutically acceptable
acceptable salt
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010171260A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011046700A (ja
JP5520158B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2010171260A priority Critical patent/JP5520158B2/ja
Priority claimed from JP2010171260A external-priority patent/JP5520158B2/ja
Publication of JP2011046700A publication Critical patent/JP2011046700A/ja
Publication of JP2011046700A5 publication Critical patent/JP2011046700A5/ja
Application granted granted Critical
Publication of JP5520158B2 publication Critical patent/JP5520158B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010171260A 2009-07-31 2010-07-30 含窒素スピロ環化合物及びその医薬用途 Active JP5520158B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010171260A JP5520158B2 (ja) 2009-07-31 2010-07-30 含窒素スピロ環化合物及びその医薬用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009179502 2009-07-31
JP2009179502 2009-07-31
JP2010171260A JP5520158B2 (ja) 2009-07-31 2010-07-30 含窒素スピロ環化合物及びその医薬用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014077850A Division JP2014141516A (ja) 2009-07-31 2014-04-04 含窒素スピロ環化合物及びその医薬用途

Publications (3)

Publication Number Publication Date
JP2011046700A JP2011046700A (ja) 2011-03-10
JP2011046700A5 true JP2011046700A5 (enExample) 2014-02-13
JP5520158B2 JP5520158B2 (ja) 2014-06-11

Family

ID=43529436

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2010171260A Active JP5520158B2 (ja) 2009-07-31 2010-07-30 含窒素スピロ環化合物及びその医薬用途
JP2014077850A Pending JP2014141516A (ja) 2009-07-31 2014-04-04 含窒素スピロ環化合物及びその医薬用途
JP2015224910A Ceased JP2016029104A (ja) 2009-07-31 2015-11-17 含窒素スピロ環化合物及びその医薬用途
JP2016214954A Ceased JP2017019877A (ja) 2009-07-31 2016-11-02 含窒素スピロ環化合物及びその医薬用途
JP2018028525A Ceased JP2018111701A (ja) 2009-07-31 2018-02-21 含窒素スピロ環化合物及びその医薬用途
JP2019219283A Withdrawn JP2020033384A (ja) 2009-07-31 2019-12-04 含窒素スピロ環化合物及びその医薬用途
JP2021144545A Withdrawn JP2021183653A (ja) 2009-07-31 2021-09-06 含窒素スピロ環化合物及びその医薬用途
JP2023128376A Withdrawn JP2023138641A (ja) 2009-07-31 2023-08-07 含窒素スピロ環化合物及びその医薬用途
JP2025077764A Withdrawn JP2025109780A (ja) 2009-07-31 2025-05-08 含窒素スピロ環化合物及びその医薬用途

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2014077850A Pending JP2014141516A (ja) 2009-07-31 2014-04-04 含窒素スピロ環化合物及びその医薬用途
JP2015224910A Ceased JP2016029104A (ja) 2009-07-31 2015-11-17 含窒素スピロ環化合物及びその医薬用途
JP2016214954A Ceased JP2017019877A (ja) 2009-07-31 2016-11-02 含窒素スピロ環化合物及びその医薬用途
JP2018028525A Ceased JP2018111701A (ja) 2009-07-31 2018-02-21 含窒素スピロ環化合物及びその医薬用途
JP2019219283A Withdrawn JP2020033384A (ja) 2009-07-31 2019-12-04 含窒素スピロ環化合物及びその医薬用途
JP2021144545A Withdrawn JP2021183653A (ja) 2009-07-31 2021-09-06 含窒素スピロ環化合物及びその医薬用途
JP2023128376A Withdrawn JP2023138641A (ja) 2009-07-31 2023-08-07 含窒素スピロ環化合物及びその医薬用途
JP2025077764A Withdrawn JP2025109780A (ja) 2009-07-31 2025-05-08 含窒素スピロ環化合物及びその医薬用途

Country Status (36)

Country Link
US (4) US8609647B2 (enExample)
EP (3) EP3181570A1 (enExample)
JP (9) JP5520158B2 (enExample)
KR (1) KR101773208B1 (enExample)
CN (1) CN102510865B (enExample)
AR (1) AR077497A1 (enExample)
AU (1) AU2010278066B2 (enExample)
BR (1) BR112012002157B1 (enExample)
CA (1) CA2767899C (enExample)
CO (1) CO6491052A2 (enExample)
CY (2) CY1118747T1 (enExample)
DK (1) DK2460806T3 (enExample)
ES (1) ES2616705T3 (enExample)
FI (1) FIC20250012I1 (enExample)
FR (1) FR25C1010I2 (enExample)
HR (1) HRP20170447T1 (enExample)
HU (2) HUE033070T2 (enExample)
IL (1) IL217048A (enExample)
LT (2) LT2460806T (enExample)
ME (1) ME02667B (enExample)
MX (1) MX2012001313A (enExample)
MY (1) MY163495A (enExample)
NL (1) NL301321I2 (enExample)
NO (1) NO2025014I1 (enExample)
NZ (1) NZ597994A (enExample)
PE (1) PE20121276A1 (enExample)
PL (1) PL2460806T3 (enExample)
PT (1) PT2460806T (enExample)
RS (1) RS55913B1 (enExample)
RU (1) RU2630694C2 (enExample)
SG (1) SG176918A1 (enExample)
SI (1) SI2460806T1 (enExample)
SM (1) SMT201700166T1 (enExample)
TW (1) TWI466885B (enExample)
WO (1) WO2011013785A1 (enExample)
ZA (1) ZA201200689B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
JP5749341B2 (ja) * 2010-08-20 2015-07-15 ハチソン メディファーマ リミテッド ピロロピリミジン化合物およびその使用
JP5927201B2 (ja) 2010-12-16 2016-06-01 カルチャン リミテッド Ask1阻害ピロロピリミジン誘導体
PL2796460T3 (pl) 2011-12-21 2018-12-31 Jiangsu Hengrui Medicine Co. Ltd. Sześcioczłonowa pirolowa heteroarylowa pochodna pierścieniowa, sposób jej otrzymywania i zastosowania medyczne
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
CA2948444C (en) * 2014-05-28 2022-07-26 Astrazeneca Ab Processes for the preparation of azd5363 and intermediate used therein
EP3321271B1 (en) * 2015-07-07 2024-05-29 Japan Tobacco Inc. Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
DK3352734T3 (da) * 2015-09-24 2020-03-30 Japan Tobacco Inc Behandling af alopecia areata
JP6767491B2 (ja) * 2015-09-25 2020-10-14 ディザル(ジァンスー)ファーマシューティカル・カンパニー・リミテッド Jakを阻害するための化合物及び方法
AU2017209932A1 (en) 2016-01-21 2018-07-05 Leo Pharma A/S Treatment of hand eczema
ES2974090T3 (es) 2016-08-01 2024-06-25 Tenacia Biotechnology Hong Kong Co Ltd Moduladores de NMDA de espirolactama y métodos de uso de los mismos
BR112019008812A2 (pt) * 2016-11-23 2019-07-16 Jiangsu Hengrui Medicine Co método de preparação para e intermediário de derivado de pirrolo anel heteroaromático de seis elementos
KR102702286B1 (ko) * 2016-12-21 2024-09-04 니뽄 다바코 산교 가부시키가이샤 7H-피롤로[2,3-d]피리미딘 유도체의 제조 방법 및 그의 공결정
BR112019012210A2 (pt) 2016-12-21 2019-11-12 Japan Tobacco Inc formas cristalinas de um inibidor de janus cinase
MX2019007542A (es) 2016-12-21 2019-11-18 Japan Tobacco Inc Proceso para la preparación de derivados de 7h-pirrolo [2, 3-d] pirimidina y sus intermedios sintéticos.
CN110291090A (zh) * 2017-01-20 2019-09-27 利奥制药有限公司 作为新型jak激酶抑制剂的双环胺
JP7101176B2 (ja) * 2017-02-03 2022-07-14 レオ ファーマ アクティーゼルスカブ 新規JAKキナーゼ阻害剤としての5-(7H-ピロロ[2,3-d]ピリミジン-4-イル)-5-アザスピロ[2.5]オクタン-8-カルボン酸誘導体
JP2020536898A (ja) * 2017-10-10 2020-12-17 バイオジェン インコーポレイテッド スピロ誘導体を調製するためのプロセス
AU2019215049A1 (en) * 2018-01-31 2020-09-17 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
JP2021528479A (ja) * 2018-07-06 2021-10-21 レオ ファーマ アクティーゼルスカブ ヤヌスキナーゼ阻害剤としての新規アミノ−イミダゾピリミジン誘導体およびその製薬学的用途
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
BR112021022031A2 (pt) 2019-05-15 2021-12-28 Leo Pharma As Composto, composição farmacêutica, e, formulação farmacêutica para administração tópica
WO2021025129A1 (ja) * 2019-08-07 2021-02-11 ロート製薬株式会社 涙液分泌促進用眼科組成物
TWI889740B (zh) * 2019-12-27 2025-07-11 日商樂敦製藥股份有限公司 水性組成物
CN111560021B (zh) * 2020-06-30 2023-05-26 上海鲲博玖瑞医药科技发展有限公司 一种德高替尼中间体及其制备方法
CN111574540B (zh) * 2020-06-30 2023-08-29 云南华派医药科技有限公司 一种德高替尼的制备方法
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
WO2022117075A1 (zh) * 2020-12-04 2022-06-09 广州费米子科技有限责任公司 氮杂并环化合物、其制备方法及其用途
TW202241439A (zh) * 2020-12-29 2022-11-01 大陸商上海岸闊醫藥科技有限公司 治療與抗腫瘤劑相關的皮膚疾病或病症的試劑和方法
JP2025514747A (ja) 2022-04-20 2025-05-09 レオ ファーマ アクティーゼルスカブ 前頭部線維性脱毛症の治療
WO2024180493A1 (en) 2023-02-28 2024-09-06 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
AU2024238918A1 (en) 2023-03-17 2025-10-09 Leo Pharma A/S A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema
WO2024225445A1 (en) 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib
WO2025085050A1 (en) * 2023-10-16 2025-04-24 Leo Pharma A/S Treatment of frontal fibrosing alopecia

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139787A0 (en) 1998-06-02 2002-02-10 Osi Pharm Inc PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
PL198640B1 (pl) * 1998-06-19 2008-07-31 Pfizer Prod Inc Związki pirolo[2,3-d]pirymidynowe, środek farmaceutyczny i zastosowanie tych związków
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EA006227B1 (ru) * 1999-12-10 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
EA009789B1 (ru) * 2002-07-05 2008-04-28 Таргасепт, Инк. N-арилдиазаспирациклические соединения и способы их получения и применения
EP1683797A1 (en) 2003-11-13 2006-07-26 Ono Pharmaceutical Co., Ltd. Heterocyclic spiro compound
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006090261A1 (en) 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
KR20080016659A (ko) * 2005-05-20 2008-02-21 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 피롤로피리딘
KR20080026654A (ko) * 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JP2009523812A (ja) * 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2008029237A2 (en) 2006-09-05 2008-03-13 Pfizer Products Inc. Combination therapies for rheumatoid arthritis
CN101563323B (zh) 2006-12-22 2012-07-04 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
TW200904437A (en) * 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
PE20090996A1 (es) * 2007-04-02 2009-07-15 Palau Pharma Sa Derivados de pirrolopirimidina como inhibidores de cinasa jak3
US20100298289A1 (en) * 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
TW200940542A (en) 2008-01-09 2009-10-01 Array Biopharma Inc Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
CA2728559A1 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
JP2018028525A (ja) * 2016-08-15 2018-02-22 小野 信行 イオンレーザーと重水素を利用した核融合炉
JP6229778B2 (ja) * 2016-09-21 2017-11-15 サミー株式会社 遊技機

Similar Documents

Publication Publication Date Title
RU2012106344A (ru) Азотсодержащее спироциклическое соединение и его применение в медицине
RU2017125025A (ru) Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk
RU2378263C2 (ru) Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы
JP2010535722A5 (enExample)
JP2014517017A5 (ja) 化合物、その医薬組成物、及び癌治療用の阻害薬としてのその使用
EA201001455A1 (ru) Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3)
JP2013063968A5 (enExample)
EA201391558A1 (ru) Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения
JP2007508359A5 (enExample)
MY155133A (en) Compounds having crth2 antagonist activity
RU2012127334A (ru) Производные 5-замещенного хиназолинона, содержащие их композиции и способы их применения
JP2015501799A5 (enExample)
DE60103136D1 (de) Imidazol derivate als raf kinase inhibitoren
JP2012526143A5 (enExample)
JP2011037841A5 (enExample)
JP2010506942A5 (enExample)
RU2015155585A (ru) 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента
JP2013532652A5 (enExample)
RU2012112050A (ru) Производные дигидроптеридинона, способ их получения и фармацевтическое применение
RU2013141559A (ru) Способ ингибирования клеток опухоли гамартомы
JP2016531868A5 (enExample)
JP2021522262A5 (enExample)
IN2014DN07283A (enExample)
JP2017531677A5 (enExample)
JP2015524843A5 (enExample)